首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1638836

血栓和止血生物標記市場機會、成長動力、產業趨勢分析和 2024 年至 2032 年預測

Thrombosis and Hemostasis Biomarkers Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 to 2032

出版日期: 2024年11月07日 | 出版商:

Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年，全球血栓和止血生物標記市場估值為52 億美元，預計2024 年至2032 年複合年成長率為5.8%。、生物標記研究的進步、以及個人化醫療的日益普及。人們對凝血相關病症的早期檢測和管理的認知不斷增強，進一步支持了市場的擴張。

該市場根據產品分為分析儀和試劑及消耗品，後者在 2023 年佔據主導地位，收入達 33 億美元。試劑和耗材對於診斷和研究目的至關重要，包括用於檢測和分析凝血障礙生物標記的檢測試劑盒、化學物質和緩衝液。對準確、快速的診斷工具的需求推動了對這些產品的需求，以識別深部靜脈栓塞和肺栓塞等疾病。纖維蛋白原、D-二聚體和凝血酶原時間等關鍵生物標記有助於監測凝血障礙並指導抗凝血治療。

市場也根據測試地點分為臨床實驗室測試和現場護理測試。 2023 年，臨床實驗室檢測占主導地位，佔 64.1% 這些檢測，包括凝血酶原時間、活化部分凝血活酶時間和血小板功能分析，對於診斷凝血異常和評估出血風險至關重要。心血管疾病發病率的不斷上升、人口老化和肥胖率的增加正在推動對這些診斷服務的需求。這些檢查不僅有助於評估凝血途徑，還支持血栓形成預防策略和抗凝血治療的有效管理。

市場範圍
開始年份	2023年
預測年份	2024-2032
起始值	52 億美元
預測值	87 億美元
複合年成長率	5.8%

美國血栓和止血生物標記市場預計將以5.8% 的複合年成長率成長，到2032 年將達到30 億美元。成長。研發方面的強勁投資以及精準醫療的廣泛採用，推動了對血栓和止血生物標記的需求。領先的生物技術和製藥公司的存在進一步加速了生物標記發現和商業化的進步，重點關注早期檢測和個人化治療。此外，不斷增加的醫療支出和有利的監管框架促進了創新診斷工具在臨床實踐中的採用。現場護理測試設備和非侵入性診斷方法的使用不斷增加，增強了患者護理，同時推動了市場擴張。

產業生態系統分析
產業影響力
- 成長動力
  - 心血管疾病盛行率上升
  - 生物標記測試的技術進步
  - 個人化醫療需求不斷成長
- 產業陷阱與挑戰
  - 生物標記檢測成本高
  - 新興市場意識有限
成長潛力分析
監管環境
未來市場趨勢
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：依產品分類，2021-2032 年

主要趨勢
分析儀
試劑及耗材

第 6 章：市場估計與預測：按測試地點，2021-2032 年

主要趨勢
臨床實驗室測試
現場護理測試

第 7 章：市場估計與預測：依測驗類型，2021-2032

主要趨勢
D-二聚體
抗凝血酶III
纖溶酶原
可溶性纖維蛋白
因子VIII
凝血酶後 (PT)
活化部分凝血活酶時間 (APTT) 測試
其他測試類型

第 8 章：市場估計與預測：按應用分類，2021-2032 年

主要趨勢
深部靜脈血栓 (DVT)
肺栓塞（PE）
瀰漫性血管內凝血 (DIC)
其他應用

第 9 章：市場估計與預測：依最終用途，2021-2032 年

主要趨勢
醫院和診所
診斷實驗室
其他最終用戶

第 10 章：市場估計與預測：按地區分類，2021-2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國

第 11 章：公司簡介

Abbott Laboratories
ARUP Laboratories
Biomedica Diagnostics
BioMerieux
Cincinnati Children's Hospital Medical Center
Cleveland Clinic Laboratories
Diazyme Laboratories
F. Hoffmann-La Roche
HORIBA
Mayo Clinic Laboratories
QuidelOrtho
Siemens Healthineers
Thermo Fisher Scientific
Werfen

簡介目錄

Product Code: 12202

The Global Thrombosis And Hemostasis Biomarkers Market was valued at USD 5.2 billion in 2023 and is projected to grow at a CAGR of 5.8% from 2024 to 2032. This growth is driven by the increasing prevalence of cardiovascular and clotting disorders, advancements in biomarker research, and the rising adoption of personalized medicine. The market's expansion is further supported by growing awareness of early detection and management of coagulation-related conditions.

The market is segmented based on products into analyzers and reagents & consumables, with the latter dominating in 2023, accounting for USD 3.3 billion in revenue. Reagents and consumables are crucial for diagnostic and research purposes, encompassing assay kits, chemicals, and buffers used to detect and analyze biomarkers for clotting disorders. The demand for these products is fueled by the need for accurate and rapid diagnostic tools to identify conditions such as deep vein thrombosis and pulmonary embolism. Key biomarkers like fibrinogen, D-dimer, and prothrombin time help monitor coagulation disorders and guide anticoagulant therapies.

The market is also categorized by test location into clinical laboratory tests and point-of-care tests. Clinical laboratory tests held a dominant share of 64.1% in 2023. These tests, including prothrombin time, activated partial thromboplastin time, and platelet function analysis, are vital for diagnosing clotting abnormalities and assessing bleeding risks. The growing incidence of cardiovascular diseases, an aging population, and increasing obesity rates are driving demand for these diagnostic services. These tests not only aid in evaluating coagulation pathways but also support the effective management of thrombosis prevention strategies and anticoagulant treatments.

Market Scope
Start Year	2023
Forecast Year	2024-2032
Start Value	$5.2 Billion
Forecast Value	$8.7 Billion
CAGR	5.8%

The U.S. thrombosis and hemostasis biomarkers market is projected to grow at a CAGR of 5.8%, reaching USD 3 billion by 2032. A well-established market foundation, combined with a high prevalence of cardiovascular diseases, positions the U.S. for significant growth. Robust investments in research and development, along with the widespread adoption of precision medicine, drive demand for thrombosis and hemostasis biomarkers. The presence of leading biotechnology and pharmaceutical companies further accelerates advancements in biomarker discovery and commercialization, focusing on early detection and personalized therapies. Moreover, increasing healthcare expenditures and a favorable regulatory framework promote the adoption of innovative diagnostic tools in clinical practices. The growing use of point-of-care testing devices and non-invasive diagnostic methods enhances patient care while fueling market expansion.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of cardiovascular diseases
  - 3.2.1.2 Technological advancements in biomarker testing
  - 3.2.1.3 Growing demand for personalized medicine
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of biomarker testing
  - 3.2.2.2 Limited awareness in emerging markets
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates & Forecast, By Product, 2021-2032 ($ Mn)

5.1 Key trends
5.2 Analyzers
5.3 Reagents & Consumables

Chapter 6 Market Estimates & Forecast, By Test Location, 2021-2032 ($ Mn)

6.1 Key trends
6.2 Clinical laboratory tests
6.3 Point-of-care tests

Chapter 7 Market Estimates & Forecast, By Test Type, 2021-2032 ($ Mn)

7.1 Key trends
7.2 D-dimer
7.3 Anti-thrombin III
7.4 Plasminogen
7.5 Soluble fibrin
7.6 Factor VIII
7.7 Post-Thrombin (PT)
7.8 Activated Partial Thromboplastin Time (APTT) test
7.9 Other test types

Chapter 8 Market Estimates & Forecast, By Application, 2021-2032 ($ Mn)

8.1 Key trends
8.2 Deep Vein Thrombosis (DVT)
8.3 Pulmonary Embolism (PE)
8.4 Disseminated Intravascular Coagulation (DIC)
8.5 Other applications

Chapter 9 Market Estimates & Forecast, By End Use, 2021-2032 ($ Mn)

9.1 Key trends
9.2 Hospitals and clinics
9.3 Diagnostic laboratories
9.4 Other end users

Chapter 10 Market Estimates & Forecast, By Region, 2021-2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
10.6 Middle East & Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE